Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. ELZONRIS® (tagraxofusp-erzs) was approved by the United States Food and Drug Administration, and is commercially available in the United States for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm. In addition, Co. is also assessing ELZONRIS, as both single agent and in combination, in a variety of other indications including Phase 1 and 2 clinical trials in chronic myelomonocytic leukemia, myelofibrosis, multiple myeloma, and acute myeloid leukemia. We show 33 historical shares outstanding datapoints in our coverage of STML's shares outstanding history.
Understanding the changing numbers of STML shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like STML versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching STML by allowing them to research STML shares outstanding history
as well as any other stock in our coverage universe. |
Free STML Email Alerts:
Video: Shares Outstanding Importance
